Lomefloxacin Pregnancy and Breastfeeding Warnings

Brand names: Maxaquin

Lomefloxacin Pregnancy Warnings

Lomefloxacin has been assigned to pregnancy category C by the FDA. Some animal studies failed to reveal evidence of fetal harm; however, studies using high doses demonstrated fetotoxicity and teratogenicity. There are no controlled data in human pregnancies. Cartilage damage and arthropathies have been reported in immature animals giving rise to concern over effects on fetal bone formation. Because safer alternatives are available, some experts consider fluoroquinolones contraindicated during pregnancy, especially during the first trimester. The manufacturer recommends that lomefloxacin should only be given during pregnancy when benefit outweighs risk.

Of 549 cases reported by the European Network of Teratology Information Services involving exposure to other fluoroquinolones, congenital malformations were reported in 4.8%; however, this was not higher than the background rate.

See references

Lomefloxacin Breastfeeding Warnings

It is not known whether lomefloxacin is excreted in human milk. Other fluoroquinolones are excreted into human milk and lomefloxacin is excreted into rat milk. Quinolone-induced cartilage erosion and arthropathies that have been observed in juvenile animals render some concern over its possible toxic effects on the developing joints of nursing infants. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See references

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer